论文部分内容阅读
目的观察化疗期间序贯给予厄洛替尼对晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法 58例NSCLC晚期患者化疗期间序贯给予厄洛替尼150mg/d,给药至疾病进展或不良反应无法耐受。采用实体瘤的疗效评价标准评价疗效。结果 58例患者中客观有效率为27.6%(16/58),疾病控制率为80.0%(47/58)。主要的不良反应有皮疹、腹泻和血液系统毒性。主要的不良反应有皮疹、腹泻和血液系统毒性,皮疹多为炎性脓疱疹,常分布于颜面部、颈部、躯干和四肢等。36例出现皮疹,占62.1%。血液系统毒性主要表现为白细胞和血小板减少。结论化疗期间序贯给予厄洛替尼治疗晚期NSCLC的近期疗效较好,不良反应耐受性好,远期疗效需进一步观察。
Objective To observe the efficacy and adverse reactions of erlotinib given sequentially to patients with advanced non-small cell lung cancer (NSCLC) during chemotherapy. Methods 58 patients with advanced NSCLC during chemotherapy were given sequential erlotinib 150mg / d, administered to the disease progression or adverse reactions can not tolerate. Efficacy evaluation criteria using solid tumors evaluation of efficacy. Results The objective efficiency of 58 patients was 27.6% (16/58), the disease control rate was 80.0% (47/58). The main adverse reactions are rash, diarrhea and hematological toxicity. The main adverse reactions were rash, diarrhea and hematological toxicity. Most of the rashes were inflammatory impetigo, often distributed on the face, neck, trunk and limbs. 36 cases of rash, accounting for 62.1%. Hematological toxicity mainly manifested as leukopenia and thrombocytopenia. Conclusion Sequential administration of erlotinib in the treatment of advanced NSCLC during chemotherapy has good short-term curative effect, good tolerability of adverse reactions, and long-term curative effect needs further observation.